First Generative AI Drug Enters Phase II Trials (IMAGE)

InSilico Medicine

First Generative AI Drug Enters Phase II Trials

Caption

Insilico Medicine has completed the first dose in patients in the Phase II clinical trial of INS018_055, marking the world's first anti-fibrotic small molecule inhibitor discovered and designed using generative AI

Credit

Insilico Medicine

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.